- Service Name
GENFIT
- Industry
Biopharmaceutical, Healthcare, Rare Diseases, Liver Diseases
- Main Value Proposition
GENFIT offers innovative therapeutic solutions that significantly improve the lives of patients suffering from rare and life-threatening liver diseases.
- Description
GENFIT is a late-stage biopharmaceutical company focused on developing innovative treatments for rare and life-threatening liver diseases. The company specializes in addressing high unmet medical needs through its diverse pipeline of therapeutic and diagnostic solutions.
- Key Features
First-in-Class Treatment for Primary Biliary Cholangitis (PBC); Strong pipeline with five assets in development for Acute-on-Chronic Liver Failure (ACLF); Expertise in regulatory affairs and market access; Focus on both therapeutic and diagnostic solutions
- Use Cases
Treatment of Acute-on-Chronic Liver Failure (ACLF); Management of Primary Biliary Cholangitis (PBC); Addressing complications associated with liver diseases
- Competitive advantages
First-in-Class treatment with FDA and EU approvals; Comprehensive pipeline addressing multiple liver disease indications; Expertise in navigating expedited regulatory pathways
- Strengths
GENFIT's strengths lie in its innovative drug development capabilities, strong partnerships, and a commitment to addressing high unmet medical needs in liver diseases.
- Positioning
GENFIT positions itself as a leader in the biopharmaceutical industry, specifically targeting rare and life-threatening liver diseases with high unmet medical needs.
- Audience
The primary audience includes healthcare professionals, patients with liver diseases, and stakeholders in the biopharmaceutical industry.
- CTA
Learn more in our Press Release
- Tags
Liver Diseases
Biopharmaceutical
Innovative Treatments
Patient Care
- Tagline
Aiming to Improve the Lives of Patients with ACLF and Other Life-Threatening Liver Diseases
- Tone of Voice
Professional, Compassionate, Innovative
- Differentiation
GENFIT is a pioneer in the field of liver diseases, leveraging over two decades of scientific heritage and a strong track record in drug development, making it a leader in ACLF treatment.
- Brand Positioning
GENFIT's brand identity is centered around innovation, patient-centric solutions, and a commitment to improving health outcomes in liver disease.
- Founded
1999-09-01
- Founders
Bart Staels
Florence Séjourné
Jean-François Mouney